Former Affymetrix CFO Tim Barabe has joined the board of directors of Opexa Therapeutics, a Woodlands, Texas-based biotechnology company.
Barabe retired from his role as CFO and executive vice president last year. Before joining the microarray vendor, he was also CFO of Human Genome Sciences and Regent Medical Ltd.
Barabe also serves on the board of ArQule, a Boston-based biotech company, Opexa said.
HTG Molecular Diagnostics has appointed Lewis Shuster to its board of directors.
Shuster is CEO of Shuster Capital, a strategic and operating advisory firm to life science company executives and investors based in Encinitas, Calif. He served previously as president of Invitrogen's Genomics division, CEO of Kemia, as well as CFO of Human Genome Sciences and Pharmacopeia.
He is currently a board member with Response Biomedical, Mast Therapeutics, Cleave Biosciences and MSN Healthcare.